Prospective Study on the Use of Transdermal Analgesic Buprenorphine Patches for Chronic Pain in the UK
The primary objective of the study is the descriptive analysis of incidence & severity of side effects & reasons for discontinuation of the treatment of chronic pain with transdermal analgesic Buprenorphine patches.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
- The incidence and severity of side effects [ Time Frame: patients observed for 6 months ] [ Designated as safety issue: No ]Descriptive analysis of incidence and severity of side effects and reasons for discontinuation with Buprenorphine patches. Safety Issue - No
- Treatment patterns [ Time Frame: patients observed for 6 months ] [ Designated as safety issue: No ]Insight into patient profiles treatment patterns and satisfaction.
|Study Start Date:||November 2010|
|Study Completion Date:||January 2014|
|Primary Completion Date:||August 2013 (Final data collection date for primary outcome measure)|
750 patients that are treated with transdermal Buprenorphine patches for chronic pain will be included in the study. About 20% of patients are aimed to be patch-naive, ie have received their first prescription of transdermal analgesic patches within 1 month before inclusion in this observational study. Furthermore the study should not include more than 25% of cancer patients that are treated for chronic pain in order to ensure an appropriate mix of patient population.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01225861
|Western Infirmary, Terrent Institute|
|Glasgow, United Kingdom, G11 6NT|